Neonatal Lupus

Systemic Lupus Erythematosus

Volumn , Issue , 2011, Pages 541-571

  Buyon, Jill P ^a   Friedman, Deborah M ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960395892     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374994-9.10031-2     Document Type: Chapter

References (231)

1. Morquio L. Sur une maladie infantile et familiale characterisee par des modifications permanentes du pouls, des attaques syncopales et epileptiformes et al mort subite. Arch Med Inf 1901, 4:467-475.
2. Plant R.K., Steven R.A. Complete A-V block in a fetus. Am Heart J 1945, 30:615-618.
3. Machado M.V.L., Tynan M.J., Curry P.V.L., Allan L.D. Fetal complete heart block. Brit Heart J 1988, 60:512-515.
4. Carter J.B., Blieden L.C., Edwards J.E. Congenital heart block: Anatomic correlations and review of the literature. Arch Pathol 1974, 97:51-57.
5. Aylward R.D. Congenital heart-block. Brit Med J 1928, 943.
6. McCue C.M., Mantakas M.E., Tingelstad J.B., Ruddy S. Congenital heart block in newborns of mothers with connective tissue disease. Circulation 1977, 56:82-90.
7. Chameides L., Truex R.C., Vetter V., Rashkind W.J., Galioto F.M., Noonan J.A. Association of maternal systemic lupus erythematosus with congenital complete heart block. N Engl J Med 1977, 297:1204-1207.
8. Winkler R.B., Nora A.H., Nora J.J. Familial congenital complete heart block and maternal systemic lupus erythematosus. Circulation 1977, 56:1103-1107.
9. Lee L.A., Reed B.R., Harmon C. Autoantibodies to SS-A/Ro in congenital heart block. Arthritis Rheum 1983, 20:S24.
10. Scott J.S., Maddison P.J., Taylor P.V., Esscher E., Scott O., Skinner R.P. Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block. New Engl J Med 1983, 309:209-212.
11. Watson R.M., Lane A.T., Barnett N.K., Bias W.B., Arnett F.C., Provost T.T. Neonatal lupus erythematosus: a clinical, serological and immunogenetic study with review of the literature. Medicine (Baltimore) 1984, 63:362-378.
12. Ramsey-Goldman R., Hom D., Deng J.-S., Ziegler G.C., Kahl L.E., Steen V.D., et al. Anti-SS-A antibodies and fetal outcome in maternal systemic lupus erythematosus. Arthritis Rheum 1986, 29:1269-1273.
13. Buyon J.P., Swersky S., Fox H., Bierman F., Winchester R.J. Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus: experience in a mother with a predominance of SSB/La antibodies. Arthritis Rheum 1987, 30:44-49.
14. Silverman E.D., Mamula M.J., Hardin J.A., Laxer R.M. The importance of the immune response to the Ro/La particle in the development of complete heart block and neonatal lupus erythematosus. J Rheumatol 1991, 18:120-124.
15. Taylor P.V., Taylor K.F., Norman A., Griffiths S., Scott J.S. Prevalence of maternal Ro(SS-A) and La(SS-B) autoantibodies in relation to congenital heart block. British J Rheum 1988, 27:128-132.
16. Buyon J.P., Slade S.G., Elkon K., Chan E.K.L., Winchester R., Lockshin M. Combined assays for Ro/La identify risk of congenital heart block (CHB). Arthritis Rheum 1990, 33:S28.
17. Buyon J.P., Ben-Chetrit E., Karp S., Roubey R.A.S., Pompeo L., Reeves W.H., et al. Acquired congenital heart block: pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus. J Clin Inv 1989, 84:627-634.
18. Laxer R.M., Roberts E.A., Gross K.R., Britton J.R., Cutz E., Dimmick J., et al. Liver disease in neonatal lupus erythematosus. J Pediatr 1990, 116:238-242.
19. Watson R., Kang J.E., May M., Hudak M., Kickler T., Provost T.T. Thrombocytopenia in the neonatal lupus syndrome. Arch Dermatol 1988, 124:560-563.
20. McCuistion C.H., Schoch E.P. Possible discoid lupus erythematosus in a newborn infant. Report of a case with subsequent development of acute systemic lupus erythematosus in the mother. Arch Dermatol Syph 1954, 70:782-785.
21. Kephardt D.C., Hood A.F., Provost T.T. Neonatal lupus erythematosus: new serologic findings. J Invest Derm 1987, 77:331-333.
22. Buyon J., Szer I. Passively acquired autoimmunity and the maternal fetal dyad in systemic lupus erythematosus. Sem Immunopathol 1986, 9:283-304.
23. Brucato A., Frassi M., Franceschini F., Cimaz R., Faden D., Pisoni M.P., et al. Risk of congenital complete heart block in newborns of mothers with Anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis. A prospective study of 100 women. Arthritis Rheum 2001, 44:1832-1835.
24. Herreman G., Galezewski N. Maternal connective tissue disease and congenital heart block. (letter) New Engl J Med 1985, 312:1329.
25. Lee L.A., Coulter S., Erner S., Chu H. Cardiac immunoglobulin deposition in congenital heart block associated with maternal anti-Ro antibody. Am J Med 1987, 83:793-796.
26. Litsey S.E., Noonan J.A., O'Connor W.N., Cottrill C.M., Mitchell B. Maternal connective tissue disease and congenital heart block. Demonstration of immunoglobulin in cardiac tissue. New Engl J Med 1985, 312:98-100.
27. Ho Y.S., Esscher E., Anderson R.H., Michaelsson M. Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies. Am J Cardiol 1986, 58:291-294.
28. Hogg G.R. Congenital acute lupus erythematosus associated with subendocardial fibroelastosis: report of a case. Am J Clin Pathol 1957, 28:648-654.
29. Singsen B.H., Akhter J.E., Weinstein M.M., Sharp G.S. Congenital complete heart block and SSA antibodies: obstetric implications. Am J Obstet Gynecol 1985, 152:655-658.
30. Nield L.E., Silverman E.D., Taylor C.P., Smallhorn J.F., Mullen J.B., Silverman N.H., et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002, 105:843-848.
31. Nield L.E., Silverman E.D., Smallhorn J.F., Taylor G.P., Mullen J.B., Benson L.N., et al. Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. J Am Coll Cardiol 2002, 40:796-802.
32. Buyon J.P., Hiebert R., Copel J., Craft J., Friedman D., Katholi M., et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998, 31:1658-1666.
33. Tseng C., Friedman D., Buyon J.P. Spectrum of cardiac histopathology in cases of autoimmune-associated congenital heart block (CHB) obtained from the Research Registry for Neonatal Lupus [abstract]. Arthritis Rheum 1997, 40(Suppl):S333.
34. Clancy R.M., Kapur R.P., Molad Y., Askanase A.D., Buyon J.P. Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 2004, 50:173-182.
35. Askanase A.D., Friedman D.M., Dische M.R., Dubin A., Starc T., Katholi M.C., et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002, 11:145-151.
36. Clancy R.M., Backer C.B., Yin X., Kapur R.P., Molad Y., Buyon J.P. Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-alpha and TGF-beta 1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol 2003, 171:3253-3261.
37. Rote N.S. Maternal fetal immunology. Immunology in Obstetrics and Gynecology 1985, 55. Appelton-Crofts, Norwalk, CT. J.R. Scott, N.S. Rote (Eds.).
38. Leach J.L., Sedmak D.D., Osborne J.M., Rahill B., Lairmore M.D., Anderson C.L. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol 1996, 157:3317-3322.
39. Lin C.T., Shen Z., Boros P., Unkeless J.C. Fc receptor-mediated signal transduction. J Clin Immunol 1992, 14:1-13.
40. Wells M., Fox H. Immunology and immunopathology of the maternofetal interface. Immunological Obstetrics 1992, 166-176. W.W. Norton & Company, New York. C.B. Coulam, W.P. Faulk, J.A. McIntyre (Eds.).
41. Stiehm E.R. Fetal defense mechanisms. Am J Dis Child 1975, 129:438-443.
42. Tseng C., Caldwell K., Feit S., Chan E.K.L., Buyon J.P. Subclass distribution of maternal and neonatal anti-SSA/Ro and -SSB/La antibodies in congenital heart block. J Rheum 1996, 23:925-932.
43. James T.N. Cardiac conduction system: fetal and postnatal development. Am J Cardiol 1970, 25:213-226.
44. Deng J.S., Bair L.W., Shen-Schwartz S., Ramsey-Goldman R., Medsger T. Localization of Ro(SS-A) antigen in the cardiac conduction system. Arthritis Rheum 1987, 30:1232-1238.
45. Hübscher O., Batista N., Rivero S., Marletta C., Arriagada M., Boire G., et al. Clinical and serological identification of 2 forms of complete heart block in children. J Rheum 1995, 22:1352-1355.
46. Friedman D.M., Kim M.Y., Copel J.A., Davis C., Phoon C.K., Glickstein J.S., et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008, 29:485-493.
47. Sonesson S.E., Salomonsson S., Jacobsson L.A., Bremme K., Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004, 50:1253-1261.
48. Rein A.J., Mevorach D., Perles Z., Gavri S., Nadjari M., Nir A., et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 2009, 14:1867-1872.
49. Moak J.P., Barron K.S., Hougen T.J., Wiles H.B., Balaji S., Sreeram N., et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001, 37:238-242.
50. Neiman A.R., Lee L.A., Weston W.L., Buyon J.P. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000, 13:674-680.
51. Lee L.A. Maternal autoantibodies and pregnancy-II: The neonatal lupus syndrome. Bailliere's Clinical Rheumatology, Pregnancy and the Rheumatic Diseases 1990, 69-84. Bailliere Tindall. A.L. Parke (Ed.).
52. Thornton C.M., Eichenfield L.F., Shinall E.A., Siegfried E., Rabinowitz L.G., Esterly N.B., et al. Cutaneous telangiectases in neonatal lupus erythematosus. J Am Acad Dermatol 1995, 33:19-25.
53. Buyon J.P. Neonatal lupus. Rheumatology 1998, Mosby-Wolfe Publishers, London. 2nd ed. J.H. Klippel, P.A. Dieppe (Eds.).
54. Lee L.A., Weston W.L. Neonatal lupus erythematosus. Sem Dermatol 1988, 7:66-72.
55. Bangert J.L., Freeman R.G., Sontheimer R.D., Gilliam J.N. Subacute cutaneous lupus erythematosus and discoid lupus erythematosus: comparative histopathologic findings. Arch Dermatol 1984, 120:332-337.
56. David K.M., Bennion S.D., DeSpain J.D., Golitz L.E., Lee L.A. Immunoreactants in lesions and uninvolved skin in lupus (abstract). Clin Res 1989, 37:748A.
57. Rosh J.R., Silverman E.D., Groisman G., Dolgin S., LeLeiko N.S. Intrahepatic cholestasis in neonatal lupus erythematosus. J Pediatr Gastroenterol Nutr 1993, 17:310-312.
58. Lee L.A., Reichlin M., Ruyle S.Z., Weston W.L. Neonatal lupus liver disease. Lupus 1993, 2:333-338.
59. Lee L.A., Sokol R.J., Buyon J.P. Hepatobiliary disease in neonatal lupus erythematosus: Prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics 2002, 109:e11.
60. Schoenlebe J., Buyon J.P., Zitelli B.J., Friedman D., Greco M.A., Knisely A.S. Neonatal hemochromatosis associated with maternal autoantibodies against Ro/SS-A and La/SS-B ribonucleoproteins. Am J Dis Child 1993, 147:1072-1075.
61. Evans N., Gaskin K. Liver disease in association with neonatal lupus erythematosus. J Paed Child Health 1993, 29:478-480.
62. Wallace S.A., Aron A.M., Taff I. Neonatal lupus involving the central nervous system. Ann Neurol 1984, 16:399.
63. Moudgil A., Kishore K., Srivastava R.N. Neonatal lupus erythematosus, late onset hypocalcaemia, and recurrent seizures. Arch Dis Childhood 1987, 62:736-739.
64. Wong H.S., Kuo M.F., Chang T.C. Sonographic lenticulostriate vasculopathy in infants: some associations and a hypothesis. Am J Neuroradiol 1995, 16:97-102.
65. Bourke J.F., Burns D.A. Neonatal lupus erythematosus with persistent telangiectasia and spastic paraparesis. Clinical Exp Dermatol 1993, 18:271-273.
66. Kaye E.M., Butler I.J., Conley S. Myelopathy in neonatal and infantile lupus erythematosus. J Neurol Neurosurg Psych 1987, 50:923-926.
67. Boros C.A., Spence D., Blaser S., Silverman E.D. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum 2007, 15:261-266.
68. Kanagasegar S., Cimaz R., Kurien B.T., Brucato A., Scofield R.H. Neonatal lupus manifests as isolated neutropenia and mildly abnormal liver functions. J Rheumatol 2002, 29:187-191.
69. Wolach B., Choc L., Pomeranz A., Ben Ari Y., Douer D., Metzker A. Aplastic anemia in neonatal lupus erythematosus. Am J Dis Child 1993, 147:941-944.
70. Harley J.B. Autoantibodies in Sjögren's syndrome. J Autoimmun 1989, 2:283-394.
71. Reichlin M. Antibodies to cytoplasmic antigens. Systemic Lupus Erythematosus 1992, 237-246. Churchill Livingstone, London. 2nd ed. R. Lahita (Ed.).
72. Fritzler M.J., Pauls J.D., Kinsella T.D., Bowen T.J. Antinuclear, anticytoplasmic, and anti-Sjögren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1985, 36:120-128.
73. Harmon C.E., Lee L.A., Huff J.C., Norris D.A., Weston W.L. The frequency of autoantibodies to the SS-A/Ro antigen in pregnancy sera [abstract]. Arthritis Rheum 1984, 27:S20.
74. Keech C.L., McCluskey J., Gordon T.P. SS-B(La) autoantibodies. Autoantibodies 1996, 789-797. Elsevier, Amsterdam. J.B. Peter, Y. Shoenfeld (Eds.).
75. Ben-Chetrit E., Gandy B.J., Tan E.M., Sullivan K.F. Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A/Ro ribonucleoprotein autoantigen. J Clin Invest 1989, 83:1284-1292.
76. Deutscher S.L., Harley J.B., Keene J.D. Molecular analysis of the 60kDa human Ro ribonucleoprotein. Proc Natl Acad Sci USA 1988, 85:9479-9483.
77. Chan E.K.L., Hamel J.C., Peebles C.L., Tan E.M. Molecular heterogeneity in SS-A/Ro autoantigens. Arthritis Rheum 1990, 33:S73.
78. Lerner M.R., Boyle J.A., Hardin J.A., Steitz J.A. Two novel classes of small ribonucleoproteins detected by antibodies associated with lupus erythematosus. Science 1981, 211:400-402.
79. Wang D., Buyon J.P., Chan E.K.L. Cloning and expression of mouse 60kDa ribonucleoprotein SS-A/Ro. Mol. Biol. Reports 1996, 23:205-210.
80. Fuchs G., Stein A.J., Fu C., Reinisch K.M., Wolin S.L. Structural and biochemical basis for misfolded RNA recognition by the Ro autoantigen. Nat Struct Mol Biol 2006, 13:1002-1009.
81. O'Brien C.A., Wolin S.L. A possible role for the 60-kD Ro autoantigen in a discard pathway for defective 5s rRNA precursors. Genes and Development 1994, 8:2891-2903.
82. Chambers J.C., Kenan D., Martin B.J., Keene J.D. Genomic structure and amino acid sequence domains of the human La autoantigen. J Biol Chem 1988, 263:18043-18051.
83. Chan E.K.L., Francour A.M., Tan E.M. Epitopes, structural domains and asymmetry of amino acid residues in SS-B/La nuclear protein. J Immunol 1986, 136:3744-3749.
84. Gottlieb E., Steitz J.A. Function of the mammalian La protein: evidence for its action in transcription termination by RNA polymerase III. EMBO J 1989, 8:851-861.
85. Boire G., Craft J. Human Ro ribonucleoprotein particles: characterization of native structure and stable association with the La polypeptide. J Clin Invest 1990, 85:1182-1190.
86. Ben-Chetrit E., Chan E.K.L., Sullivan K.F., Tan E.M. A 52 kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med 1988, 162:1560-1571.
87. Chan E.K.L., Hamel J.C., Buyon J.P., Tan E.M. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J Clin Invest 1991, 87:68-76.
88. Itoh K., Itoh Y., Frank M.B. Protein heterogeneity in the human Ro/SSA ribonucleoproteins. J Clin Invest 1991, 87:177-186.
89. Wada K., Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 2006, 339:415-421.
90. Espinosa A., Dardalhon V., Brauner S., Ambrosi A., Higgs R., Quintana.F.J., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009, 206:1661-1671.
91. McCauliffe D.P., Lux A.F., Lieu T., Sanz I., Hanke J., Newkirk M.M., et al. Molecular cloning, expression, and chromosome 19 localization of a human Ro/SS-A autoantigen. J Clin Inv 1990, 85:1379-1391.
92. Fliegel L., Burns K., MacLennan D.H., Reithmeier R.A.F., Michalak M. Molecular cloning of the high affinity calcium-binding protein (calreticulin) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1989, 264:21522-21528.
93. Sontheimer R.D., Nguyen T.O., Buyon J.P., Lee L.A., Hall R.P., Yang Y.S., et al. Clinical correlations of autoantibodies to a recombinant, hYRNA-binding form of human calreticulin. [abstract]. Arthritis Rheum 1996, 39(Suppl.):S38.
94. 4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol 2000, 30:2782-2790.
95. Buyon J.P., Winchester R.J., Slade S.G., Arnett F., Copel J., Friedman D., et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Arthritis Rheum 1993, 36:1263-1273.
96. Julkunen H., Kurki P., Kaaja R., Heikkila R., Ilkka I., Chan E.K.L., et al. Isolated congenital heart block: Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. Arthritis Rheum 1993, 36:1588-1598.
97. Salomonsson S., Dörner T., Theander E., Bremme K., Larsson P., Wahren-Herlenius M. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002, 46:1233-1241.
98. Buyon J.P., Slade S.G., Reveille J.D., Hamel J.C., Chan E.K. Autoantibody responses to the "native" 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjögren's syndrome. J Immunol 1994, 152:3675-3684.
99. Clancy R.M., Buyon J.P., Ikeda K., Nozawa K., Argyle D.A., Friedman D.M., et al. Maternal antibody responses to the 52-kd SSA/Ro p200 peptide and the development of fetal conduction defects. Arthritis Rheum 2005, 52:3079-3086.
100. Strandberg L., Winqvist O., Sonesson S.E., Mohseni S., Salomonsson S., Bremme K., et al. Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 2008, 154:30-37.
101. Buyon J.P., Clancy R., Di Donato F., Miranda-Carus M.E., Askanase A.D., Garcia J., et al. Cardiac 5-HT(4) serotoninergic receptors, 52kD SSA/Ro and autoimmune-associated congenital heart block. J Autoimmun 2002, 19:79-86.
102. Kamel R., Eftekhari P., Clancy R., Buyon J.P., Hoebeke J. Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: a reassessment. J Autoimmun 2005, 25:72-76.
103. 1RNP positive neonatal lupus erythematosus: association with anti-La antibodies?. Brit J Dermatol 1995, 132:520-526.
104. 1RNP-positive antibodies in fraternal twins - Is this a subset of neonatal lupus erythematosus or a new distinct syndrome?. J Am Acad Dermatol 1995, 32:858-862.
105. Buyon J.P., Slade S.G., Chan E.K.L., Tan E.M., Winchester R.J. Effective separation of the 52 SSA/Ro polypeptide from the 48kD polypeptide by altering conditions of gel electrophoresis. J Immunologic Methods 1989, 129:207-210.
106. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
107. Dörner T., Chaoui R., Feist E., Göldner B., Yamamoto K., Hiepe F. Significantly increased maternal and fetal IgG autoantibody levels to 52 kD Ro(SS-A) and La(SS-B) in complete congenital heart block. J Autoimmunity 1995, 8:675-684.
108. Meilof J.F., Frohn-Mulder I.M.E., Stewart P.A., Szatmari A., Hess J., Veldhoven C.H.A., et al. Maternal autoantibodies and congenital heart block: No evidence for the existence of a unique heart block-associated anti-Ro/SS-A autoantibody profile. Lupus 1993, 2:239-246.
109. Silverman E.D., Buyon J., Laxer R.M., Hamilton R., Bini P., Chu J.L., et al. Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. Clin Exp Immunol 1995, 100:499-505.
110. Ben-Chetrit E., Fox R.I., Tan E.M. Dissociation of immune responses to the SS-A/Ro 52-kD and 60-kD polypeptides in systemic lupus erythematosus and Sjögrens syndrome. Arthritis Rheum 1990, 33:349-355.
111. Julkunen H., Siren M.K., Kaaja R., Kurki P., Friman C., Koskimies S. Maternal HLA antigens and antibodies to SS-A/Ro and SS-B/La. Comparison with systemic lupus erythematosus and primary Sjögren's syndrome. Brit J Rheum 1995, 34:901-907.
112. Itoh Y., Reichlin M. Autoantibodies to the Ro/SSA antigen are conformation dependent. I. Anti-60kD antibodies are mainly directed to the native protein; anti-52kD antibodies are mainly directed to the denatured protein. Autoimmunity 1992, 14:57-65.
113. Buyon J.P. Congenital complete heart block. Lupus 1993, 2:291-295.
114. Neidenbach P.J., Sahn E.E. La (SS-B)-positive neonatal lupus erythematosus: Report of a case with unusual features. J Am Acad Dermatol 1993, 29:848-852.
115. Stea E.A., Routsias J.G., Clancy R.M., Buyon J.P., Moutsopoulos H.M., Tzioufas A.G. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006, 54:2228-2234.
116. Tan E.M. Do autoantibodies inhibit function of the cognate antigens in vivo?. Arthritis Rheum 1989, 32:924-925.
117. Taylor P.V., Scott J.S., Gerlis L.M., Path F.R.C., Esscher E., Scott O. Maternal antibodies against fetal cardiac antigens in congenital complete heart block. New Engl J Med 1986, 315:667-672.
118. Harley J.B., Kaine J.L., Fox O.F., Reichlin M., Gruber B. Ro(SS-A) antibody and antigen in a patient with congenital complete heart block. Arthritis Rheum 1985, 28:1321-1325.
119. Buyon J.P., Waltuck J., Crawford B., Slade S., Copel J., Chan E.K.L. Relationship between maternal and neonatal levels of antibodies to 48 kD SSB/La, 52 kD SSA/Ro and 60 kD, SSA/Ro in pregnancies complicated by congenital heart block. J Rheumatol 1994, 21:1943-1950.
120. Alarcon-Segovia D., Ruiz-Arguelles A., Liorente L. Broken dogma: penetration of autoantibodies into living cells. Immunology Today 1996, 17:163-164.
121. Baboonian C., Venables P.J.W., Booth J., Williams D.G., Roffe L.M., Maini R.N. Virus infection induces redistribution and membrane localization of the nuclear antigen La (SS-B): a possible mechanism for autoimmunity. Clin Exp Immunol 1989, 78:454-459.
122. LeFeber W.P., Norris D.A., Ryan S.B., Huff J.C., Lee L.A., Kubo M., et al. Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest 1984, 74:1545-1551.
123. Furukawa F., Kashihara-Sawami M., Lyons M.B., Norris D.A. Binding of antibodies to the extractable nuclear antigens of SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. J Invest Dermatol 1990, 94:77-85.
124. Zhu J. Ultraviolet B irradiation and cytomegalovirus infection synergize to induce the cell surface expression of 52-kD Ro antigen. Clin Exp Immunol 1996, 103:47-53.
125. Dörner T., Hucko M., Mayet W.J., Trefzer U., Burmester G., Hiepe F. Enhanced membrane expression of the 52kD Ro (SSA) and La (SSB) antigens by human keratinocytes induced by TNF alpha. Ann Rheum Dis 1996, 54:904-909.
126. Levitz M., Young B.K. Estrogens in pregnancy. Vitamin Hormone 1977, 35:109-147.
127. Furukawa F., Lyons M.B., Lee L.A., Coulter S.N., Norris D.A. Estradiol enhances binding to cultured human keratinocytes of antibodies specific for SS-A/Ro and SS-B/La. J Immunol 1988, 141:1480-1488.
128. Wang D., Chan E.K.L. 17β-estradiol increases expression of 52-kDa and 60-kDa SS-A/Ro autoantigens in human keratinocytes and breast cancer cell line MCF-7. J Invest Dermatol 1996, 107:610-614.
129. Ciocca D.R., Vargas Roig L.M. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocrine Reviews 1995, 16:35-62.
130. Lin A.L., Shain S.A. Estrogen-mediated cytoplasmic and nuclear distribution of rat cardiovascular estrogen receptors. Arteriosclerosis 1985, 5:668-677.
131. Reichlin M., Brucato A., Frank M.B., Maddison P.J., McCubbin V.R., Wolfson-Reichlin M., et al. Concentration of autoantibodies to native 60-kd Ro/SS-A and denatured 52-kd Ro/SS-A in eluates from the heart of a child who died with congenital complete heart block. Arthritis Rheum 1994, 37:1698-1703.
132. Horsfall A.C., Venables P.J.W., Taylor P.V., Maini R.N. Ro and La antigens and maternal autoantibody idiotype on the surface of myocardial fibres in congenital heart block. J Autoimmunity 1991, 4:165-176.
133. Watanabe-Fukunaga R., Brannan C.L., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1993, 356:314-317.
134. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 1992, 13:74-76.
135. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
136. Ucker D.S. Death by suicide: one way to go in mammalian cellular development?. New Biol 1991, 3:103-109.
137. Kajstura J., Cheng W., Reiss K., Clark W.A., Sonneblick E.H., Krajewski S., et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996, 74:86-107.
138. Cheng W., Li B., Kajstura J., Li P., Wolin M.S., Sonneblick E.H., et al. Stretch-induced programmed myocyte cell death. J Clin Invest 1995, 96:2247-2259.
139. Pexeider T. Cell death in the morphogenesis and teratogenesis of the heart. Adv Anat Embryo Cell Bio 1975, 51:1-100.
140. Takeda K., Yu Z.X., Nishikawa T., Tanaka M., Hosoda S., Ferrans V.J., et al. Apoptosis and DNA fragmentation in the bulbus cordis of the developing rat heart. J Mol Cell Cardiol 1996, 28:209-215.
141. James T.N. Normal and abnormal consequences of apoptosis in the human heart: from postnatal morphogenesis to paroxysmal arrhythmias. Circulation 1994, 90:556-573.
142. Miranda-Carús M.E., Dinu Askanase A., Clancy R.M., Di Donato F., Chou T.M., Libera M.R., et al. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of tumor necrosis factor α by macrophages. J Immunol 2000, 165:5345-5351.
143. Clancy R.M., Neufing P.J., Zheng P., O'Mahony M., Nimmerjahn F., Gordon T.P., et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 2006, 116:2413-2422.
144. Tran H.B., Ohlsson M., Beroukas D., Hiscock J., Bradley J., Buyon J.P., et al. Subcellular redistribution of La(SS-B) autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system: a clue to the pathogenesis of congenital heart block. Arthritis Rheum 2002, 46:202-208.
145. Tran H.B., Macardle P.J., Hiscock J., Cavill D., Bradley J., Buyon J.P., et al. Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum 2002, 46:1572-1579.
146. Clancy R.M., Askanase A.D., Kapur R.P., Chiopelas E., Azar N., Miranda-Carus M.E., et al. Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 2002, 169:2156-2163.
147. Reed J.H., Neufing P.J., Jackson M.W., Clancy R.M., Macardle P.J., Buyon J.P., et al. Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes. Clin Exp Immunol 2007, 148:153-160.
148. Reed J.H., Giannakopoulos B., Jackson M.W., Krilis S.A., Gordon T.P. Ro 60 functions as a receptor for beta(2)-glycoprotein I on apoptotic cells. Arthritis Rheum 2009, 60:860-869.
149. Nicholson-Weller A., Burge J., Fearon D.T., Weller P.F., Austen K.F. Isolation of a human erythrocyte membrane glycoprotein with decay accelerating activity for C3 convertases of the complement system. J Immunol 1982, 129:184-189.
150. Ballard L.L., Bora N.S., Yu G.H., Atkinson J.P. Biochemical characterization of membrane cofactor protein of the complement system. J Immunol 1988, 141:3923-3929.
151. Ojicius D.M., Jiang S., Young J.D.E. Restriction factors of homologous complement: a new candidate?. Immunol Today 1990, 11:47-49.
152. Seya T., Turner J.R., Atkinson J.P. Purification and characterization of a membrane protein (gp 45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 1986, 163:837-855.
153. Seya T., Ballard L., Bora N., McNearney T., Atkinson J.P. Membrane cofactor protein (MCP or gp 45-70): a distinct complement regulatory protein with a wide tissue distribution. Complement 1987, 4:225.
154. Gorelick A., Oglesby T., Rashbaum W., Atkinson J., Buyon J.P. Ontogeny of membrane cofactor protein: phenotypic divergence in the fetal heart. Lupus 1995, 4:293-296.
155. Alexander E., Buyon J.P., Provost T.T., Guarnieri T. Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome, an experimental model: in vitro electrophysiologic and immunocytochemical studies. Arthritis Rheum 1992, 35:176-189.
156. Garcia S., Nascimento J.H.M., Bonfa E., Levy R., Oliveira S.F., Tavares A.V., et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994, 93:718-724.
157. Boutjdir M., Chen L., Zhang Z., Tseng C., DiDonato F., Rashbaum W., et al. Arrhythmogenicity of IgG and anti-52kD SSA/Ro affinity purified antibodies from mothers of children with congenital heart block. Circ Res 1997, 80:354-362.
158. Xiao G.Q., Hu K., Boutjdir M. Direct inhibition of expressed cardiac L- and T-type calcium channels by IgG from mothers whose children have congenital heart block. Circulation 2001, 103:1599-1604.
159. Karnabi E., Qu Y., Wadgaonkar R., Mancarella S., Yue Y., Chahine M., et al. Congenital heart block: Identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun 2009, 34:80-86.
160. Mahony L. Development of myocardial structure and function. Moss and Adams Heart Disease in Infants, Children, and Adolescents, Including the Fetus and Young Adults 1995, Volume I:17-28. Williams and Wilkins, Baltimore. 5th ed. G.C. Emmanouilides, T.A. Riemenschneider, H.D. Allen, H.P. Gutgesell (Eds.).
161. Josephson I.R., Sperelakis N. Initiation and propagation of the cardiac action potential. Physiology 1993, 251-269. Little, Brown and Co, Boston. N. Sperelakis, R.O. Banks (Eds.).
162. Mazel J.A., El-Sherif N., Buyon J., Boutjdir M. Electrocardiographic abnormalities in a murine model injected with IgG from mothers of children with congenital heart block. Circulation 1999, 99:1914-1918.
163. Kalush F., Rimon E., Keller A., Mozes E. Neonatal lupus erythematosus with cardiac involvement in offspring of mothers with experimental systemic lupus erythematosus. J Clin Immunol 1994, 14:314-322.
164. Miranda-Carús M.E., Boutjdir M., Tseng C.E., DiDonato F., Chan E.K.L., Buyon J.P. Induction of antibodies reactive with SSA/Ro-SSB/La and development of congenital heart block in a murine model. J Immunol 1998, 161:5886-5892.
165. Salomonsson S., Sonesson S.E., Ottosson L., Muhallab S., Olsson T., Sunnerhagen M., et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005, 201:11-17.
166. Gawkrodger D.J., Beveridge G.W. Neonatal lupus erythematosus in four successive siblings born to a mother with discoid lupus erythematosus. British J Dermatol 1984, 111:683-687.
167. Cooley H.M., Keech C.L., Melny B.J., Menahem S., Morahan G., Kay T.W. Monozygotic twins discordant for congenital complete heart block. Arthritis Rheum 1997, 40:381-384.
168. Siren M.K., Julkunen H., Kaaja R., Ekblad H., Koskimies S. Role of HLA in congenital heart block: susceptibility alleles in children. Lupus 1999, 8:60-67.
169. Rios B., Duff J., Simpson J.W. Endocardial fibroelastosis with congenital complete heart block in identical twins. Am Heart J 1984, 107:1290-1293.
170. Barquero Genoves I.M., Figueras Aloy J., Guerola Serret M., Jimenez Gonzalez R. A complete congenital heart block in twins. An Esp Pediatr 1996, 44:164-166.
171. Machado M.V.L., Tynan M.J., Curry P.V.L., Allan L.D. Fetal complete heart block. Brit Heart J 1988, 60:512-515.
172. McCue C.M., Mantakas M.E., Tingelstad J.B. Congenital heart block in newborns of mothers with connective tissue disease. Circulation 1977, 56:82-90.
173. Silverman E.D. Congenital heart block and neonatal lupus erythematosus: prevention is the goal. J Rheumatol 1993, 20:1101-1104.
174. Harley J.B., Alexander E.L., Bias W.B., Fox O.F., Provost T.T., Reichlin M., et al. Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren's syndrome. Arthritis Rheum 1986, 29:196-206.
175. Brucato A., Gasparini M., Vignati G., Riccobono S., De Juli E., Quinzanini M., et al. Isolated congenital heart block: longterm outcome of children and immunogenetic study. J Rheum 1995, 22:541-543.
176. Kaaja R., Julkunen H., Ammala P., Kurki P., Koskimies S. Congenital heart block in one of the HLA identical twins. Eur J Obstet Gynecol Reprod Biol 1993, 51:78-80.
177. Eronen M., Siren M.K., Ekblad H., Tikanoja T., Julkunen H., Paavilainen T. Short- and long-term outcome of children with congenital complete heart block diagnosed in utero or as a newborn. Pediatrics 2000, 106(1 Pt 1):86-91.
178. Lockshin M.D., Bonfa E., Elkon K., Druzin.M.L. Neonatal risk to newborns of mothers with systemic lupus erythematosus. Arthritis Rheum 1988, 31:697-701.
179. Llanos C., Izmirly P., Katholi M., Clancy R.M., Friedman D.M., Kim M.Y., et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009, 60:3091-3097.
180. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
181. Colombo G., Brucato A., Coluccio E., Compasso S., Luzzana C., Franceschini F., et al. DNA typing of maternal HLA in congenital complete heart block: comparison with systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum 1999, 42:1757-1764.
182. Miyagawa S., Shinohara K., Kidoguchi K., Fujita T., Fukumoto T., Yamashina Y., et al. Neonatal lupus erythematosus: HLA-DR and -DQ distributions are different among the groups of anti-Ro/SSA-positive mothers with different neonatal outcomes. J Invest Dermatol 1997, 108(6):881-885.
183. Lee L.A., Bias W.B., Arnett F.C., Huff C., Norris D.A., Harmon C., et al. Immunogenetics of the neonatal lupus syndrome. Ann Intern Med 1983, 99:592-596.
184. Brucato A., Franceschini F., Gasparini M., De Juli E., Ferraro G., Quinzanini M., et al. Isolated congenital complete heart block: longterm outcome of mothers, maternal antibody specificity and immunogenetic background. J Rheum 1995, 22:533-540.
185. Hamilton R.G., Harley J., Bias W., Roebber M., Reichlin M., Hochberg M., et al. Two Ro(SS-A) autoantibody responses in SLE. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro(SSA) autoantibody. Arthritis Rheum 1988, 31:496-505.
186. Arnaiz-Villena A., Vazquez-Rodriguez J.J., Vicario J.L., Lavilla P., Pascual D., Moreno F., et al. Congenital heart block immnogenetics: Evidence of an additional role of HLA class III antigens and independence of Ro autoantibodies. Arthritis Rheum 1989, 32:1421-1426.
187. Miyagawa S., Fukumoto T., Hashimoto K., Yoshioka A., Shirai T., Shinohara K., et al. Neonatal lupus erythematosus: haplotypic analysis of HLA class II alleles in child/mother pairs. Arthritis Rheum 1997, 40:982-983.
188. Stevens A.M., Hermes H.M., Rutledge J.C., Buyon J.P., Nelson J.L. Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 2003, 15:1617-1623.
189. McCune A.B., Weston W.L., Lee L.A. Maternal and fetal outcome in neonatal lupus erythematosus. Ann Intern Med 1987, 106:518-523.
190. Press J., Uziel Y., Laxer R.M., Luy L., Hamilton R.M., Silverman E.D. Long-term outcome of mothers of children with complete congenital heart block. Am J Med 1996, 100:328-332.
191. Lawrence S., Luy L., Laxer R., Krafchik B., Silverman E. The health of mothers with cutaneous neonatal lupus erythematosus differs from that of mothers with congenital heart block. Am J Med 2000, 15:705-709.
192. Rivera T.L., Izmirly P.M., Birnbaum B.K., Byrne P., Brauth J.B., Katholi M., et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis 2009, 68:828-835.
193. Spence D., Hornberger R.L., Hamilton R., Silverman E.D. Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies. J Rheumatol 2006, 33:167-170.
194. Askanase A.D., Iloh I., Buyon J.P. Hypothyroidism and antithyroglobulin and antithyroperoxidase antibodies in the pathogenesis of autoimmune associated congenital heart block. J Rheumatol 2006, 33:2099.
195. Geggel R.L., Tucker L., Szer I. Postnatal progression from second- to third-degree heart block in neonatal lupus syndrome. J Pediatr 1988, 113:1049-1052.
196. Bierman F.Z., Baxi L., Jaffe I., Driscoll J. Fetal hydrops and congenital complete heart block: response to maternal steroid. J Pediatr 1988, 112:646-648.
197. Saleeb S., Copel J., Friedman D., Buyon J.P. Comparison of treatment with fluorinated glucocorticoids to natural history of autoantibody-associated congenital heart block: Retrospective review of the Research Registry for Neonatal Lupus. Arthritis Rheum 1999, 42:2335-2345.
198. Friedman D.M., Kim M.Y., Copel J.A., Llanos C., Davis C., Buyon J.P. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009, 103:1102-1106.
199. Jaeggi E.T., Fouron J.C., Silverman E.D., Ryan G., Smallhorn J., Hornberger L.K. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004, 110:1542-1548.
200. Breur J.M., Visser G.H., Kruize A.A., Stoutenbeek P., Meijboom E.J. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 2004, 24:467-472.
201. Brucato A., Astori M.G., Cimaz R., Villa P., Li Destri M., Chimini L., et al. Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero. Ann Rheum Dis 2006, 65:1422-1426.
202. Airo' P., Scarsi M., Brucato A., Benicchi T., Malacarne F., Cavazzana I., et al. Characterization of T-cell population in children with prolonged fetal exposure to dexamethasone for anti-Ro/SS-A antibodies associated congenital heart block. Lupus 2006, 15:553-561.
203. Buyon J., Roubey R., Swersky S., Pompeo L., Parke A., Baxi L., et al. Complete congenital heart block: risk of occurrence and therapeutic approach to prevention. J Rheum 1988, 15:1104-1108.
204. Waltuck J., Buyon J.P. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994, 120:544-551.
205. Blanford A.T., Pearson Murphy B.E. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977, 127:264-267.
206. Shinohara K., Miyagawa S., Fujita T., Aono T., Kidoguchi K. Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol 1999, 93:952-957.
207. Barclay C.S., French M.A.H., Ross L.D., Sokol R.J. Successful pregnancy following steroid therapy and plasma exchange in a woman with anti-Ro (SS-A) antibodies. Case report. Br J Obstet Gynecol 1987, 94:369-371.
208. Kaaja R., Julkunen H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. Arthritis Rheum 2004, 50:280-281.
209. Looney R.J., Huggins J. Use of intravenous immunoglobulin (IVIG). Best Practice Res Clin Haematol 2006, 18:3-25.
210. Li N., Zhao M., Hilario-Vargas J., Prisayanh P., Warren S., Diaz L.A., et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005, 115:3440-3450.
211. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:445-446.
212. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008, 50:19571-19578.
213. Friedman D.M., Llanos C., Izmirly P.M., Brock B., Byron J., Copel J., et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block. Arthritis Rheum 2010, 1138-1146. 62n.
214. Pisoni C.N., Brucato A., Ruffatti A., Espinosa G., Cervera R., Belmonte-Serrano M., et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010, 62(4):1147-1152.
215. Askanase A.D., Miranda-Carus M.E., Tang X., Katholi M., Buyon J.P. The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: Implications in neonatal lupus. Arthritis Rheum 2002, 46:269-271.
216. Ryan A.S. The resurgence of breastfeeding in the United States. Pediatrics 1997, 99:E12.
217. Klauninger R., Skog A., Horvath L., Winqvist O., Edner A., Bremme K., et al. Serologic follow-up of children born to mothers with Ro/SSA autoantibodies. Lupus 2009, 18:792-798.
218. Hochberg M., Florsheim P., Scott J., Arnett F. Familial aggregation of systemic lupus erythematosus. Am J Epidemiol 1985, 122:526-527.
219. Lawrence J.S., Martins L., Drake G. A family survey of lupus erythematosus: 1. Heritability J Rheumatol 1987, 14:913-921.
220. Block S.R., Winfield J.B., Lockshin M.D., D'Angelo W.A., Christian C.L. Studies of twins with systemic lupus erythematosus: A review of the literature and presentation of 12 additional sets. Am J Med 1975, 59:533-552.
221. Arnett F.C., Shulman L.E. Studies in familial systemic lupus erythematosus. Medicine 1976, 55:313-322.
222. Deapen D., Escalante A., Weinrib L., Horwitz D., Bachman B., Roy-Burman P., et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992, 35:311-318.
223. Shoenfeld Y., Slor H., Shafrir S., Krause I., Granados J., Villarreal G.M., et al. Diversity and pattern of inheritance of autoantibodies in families with multiple cases of systemic lupus erythematosus. Ann Rheum Dis 1992, 51:611-618.
224. Martin V., Lee L.A., Askanase A.D., Katholi M., Buyon J.P. Long term follow-up of children with neonatal lupus and their unaffected siblings. Arthritis Rheum 2002, 46:2377-2383.
225. Esscher E., Scott J.S. Congenital heart block and maternal systemic lupus erythematosus. Brit Med J 1979, 1:1235-1238.
226. Jackson R., Gulliver M. Neonatal lupus erythematosus progressing into systemic lupus erythematosus. A 15 year follow-up. Br J Dermatol 1979, 101:81-86.
227. Fox R.J., McCuistion C.H., Schoch E.P. Systemic lupus erythematosus. Association with previous neonatal lupus erythematosus [abstract]. Arch Dermatol 1979, 115:340.
228. Waterworth R.F. Systemic lupus erythematosus occurring with congenital complete heart block. N Z Med J 1980, 92:311-312.
229. Lanham J.G., Walport M.J., Hughes G.R. Congenital heart block and familial connective disease. J Rheumatol 1983, 10:823-825.
230. Hübscher O., Carrillo D., Reichlin M. Congenital heart block and subsequent connective tissue disorder in adolescence. Lupus 1997, 6:283-284.
231. Izmirly P.M., Llanos C., Lee L.A., Askanase A., Kim M.Y., Buyon J.P. Cutaneous manifestations of neonatal lupus and risk for subsequent congenital heart block. Arthritis Rheum 2010, 2010(62):1153-1157.